Allena Pharmaceuticals Announces
New Meeting Date and New Record Date for
Special Meeting to Approve Reverse Stock Split
NEWTON, Mass., July 12, 2022 (GLOBE NEWSWIRE) Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company
dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today
announced that it has rescheduled its special meeting to, among other things, consider and vote on a proposed amendment to its amended and restated certificate of incorporation, as amended, in order to effect a reverse stock split of its issued and
outstanding common stock.
The Special Meeting will now be held on August 4, 2022, at 9:00 a.m., local time via live webcast. The new record date for
the meeting is July 12, 2022.
Allena will shortly begin mailing a copy of a new notice of special meeting, the original proxy statement for the
special meeting and a proxy statement supplement to stockholders of record and stockholders who hold shares in street name through a bank, broker or other institution, in each case as of the new record date.
About Allena Pharmaceuticals, Inc.
Allena
Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class, oral biologic therapeutics to treat
patients with rare and severe metabolic and kidney disorders.
Additional Information and Where to Find It
In connection with the special meeting described above the Company filed a definitive proxy statement with the Securities and Exchange Commission on
May 24, 2022 and in connection with the rescheduled meeting the Company will file with the Securities and Exchange Commission a supplement to the definitive proxy statement. This press release does not contain all the information that should be
considered concerning the matters to be considered at the special meeting, including the proposed reverse stock split, and is not intended to form the basis of any investment decision or any other decision in respect of such matters
The Companys stockholders and other interested persons are advised to read the definitive proxy statement and, when available, the proxy supplement, and
any amendments thereto, and any other documents filed in connection with the matters to be considered at the special meeting, including the proposed reverse stock split, as these materials will contain important information about the Company and
such matters. The Companys stockholders will also be able to obtain copies of these documents filed with the SEC, without charge, once available, at the SECs website at www.sec.gov, or by directing a request to the Companys
corporate secretary c/o Allena Pharmaceuticals, Inc., One Newton Executive Park, Suite 202, Newton, MA 02462.
Appointment of Proxy
Solicitor & Participants in Solicitation
The Company has engaged Saratoga Proxy Consulting LLC (Saratoga) to assist us with the
solicitation of proxies in connection with the special meeting. We expect to pay Saratoga a fee of $25,000, plus reimbursement for certain expenses related to its services.
The Company and its directors and executive officers may also be deemed participants in the solicitation of proxies from the Companys stockholders with
respect to the special meeting. A list of the names of those directors and executive officers and a description of their interests in the Company is contained in the Companys Annual Report for the year ended December 31, 2021 on Form 10-K, as amended, which was filed with the SEC and is available free of charge at the SECs web site at www.sec.gov. To the extent such holdings of the Companys securities may have changed since that
time, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding the interests of such participants will be contained in the definitive proxy statement, proxy
supplement and any amendments thereto and any other documents filed in connection with the rescheduled special meeting when available.
Forward Looking
Statements
Certain information contained in this press release includes forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995, including statements related to the rescheduled special meeting. We may, in some cases, use terms such as predicts, believes, potential, continue,
anticipates, estimates, expects, plans, intends, may, could, might, will, should or other words that convey uncertainty of the
future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and
uncertainties. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties, including, among others, the failure to obtain stockholder
approval for the proposed reverse stock split and various other factors. For a more detailed description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as
risks relating to our business in general, please refer to our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. You are cautioned not to place
undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.